Inhibitory effects of phthalimide derivatives on the activity of the hepatic cytochrome P450 monooxygenases CYP2C9 and CYP2C19

References

• Silverman WA. The schizophrenic career of a ‘monster drug’. Pediatrics 2002;110:404–406.
   PubMed Web of Science ®Google Scholar
• Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004;4:314–322.
   PubMed Web of Science ®Google Scholar
• Lepper ER, Smith NF, Cox MC, Scripture CD, Figg WD. Thalidomide metabolism and hydrolysis: Mechanisms and implications. Curr Drug Metabol 2006;7:677–685.
   PubMed Web of Science ®Google Scholar
• D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082–4085.
   PubMed Web of Science ®Google Scholar
• Moreira AL, Sampaio EP, Zmuidinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med 1993;177:1675–1680.
   PubMed Web of Science ®Google Scholar
• Braun AG, Weinreb SL. Teratogen metabolism: Spontaneous decay products of thalidomide and thalidomide analogues are not bioactivated by liver microsomes. Teratog Carcinog Mutagen 1985;5:149–158.
   PubMedGoogle Scholar
• Melchert M, List A. The thalidomide saga. Int J Biochem Cell Biol 2007;39:1489–1499.
   PubMed Web of Science ®Google Scholar
• Ando Y, Fuse E, Figg WD. Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 2002;8:1964–1973.
   PubMed Web of Science ®Google Scholar
• Ando Y, Price DK, Dahut WL, Cox MC, Reed E, Figg WD. Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol Therapy 2002;1:669–673.
   PubMed Web of Science ®Google Scholar
• Braun AG, Harding FA, Weinreb SL. Teratogen metabolism: Thalidomide activation is mediated by cytochrome P-450. Toxicol Appl Pharmacol 1986;82:175–179.
   PubMed Web of Science ®Google Scholar
• Teo SK, Sabourin PJ, Kook KA, Thomas SD. Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen’s disease patients. J Biochem Mol Toxicol 2000;14:140–147.
   PubMed Web of Science ®Google Scholar
• Li Y, Hou J, Jiang H, Wang D, Fu W, Yuan Z, Chen Y, Zhou L. Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide-based regimens in multiple myeloma cells. Haematologica 2007; 92:1246–1249.
   PubMed Web of Science ®Google Scholar
• Li YH, Hou J, Jiang H, Huang HM. Antiangiogenic activity of thalidomide in vitro mediated by cytochrome CYP2C19. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2009;17:102–106.
   PubMedGoogle Scholar
• Li YH, Hou J, Jiang H, Huang HM, Zhu R. Effect of cytochrome CYP2C19 on the antimyeloma activity of thalidomide in vitro. Zhonghua Xue Ye Xue Za Zhi 2008;29:654–657.
   PubMedGoogle Scholar
• Okada Y, Murayama N, Yanagida C, Shimizu M, Guengerich FP, Yamazaki H. Drug interactions of thalidomide with midazolam and cyclosporine A: Heterotropic cooperativity of human cytochrome P450 3A5. Drug Metabol Dispos 2009;37:18–23.
   PubMed Web of Science ®Google Scholar
• Aragon-Ching JB, Li H, Gardner ER, Figg WD. Thalidomide analogues as anticancer drugs. Recent Pat Anticancer Drug Discov 2007;2:167–174.
   PubMed Web of Science ®Google Scholar
• Kumar G, Lau H, Laskin O. Lanelidomide: in vitro evaluation of the metabolism and assessment of P450 cytochrome inhibition and induction. Cancer Chemother Pharmacol 2009;63:1171–1175.
   PubMed Web of Science ®Google Scholar
• Neumann H, von Wangelin AJ, Gördes D, Spannenberg A, Beller M. A new multicomponent coupling of aldehydes, amides, and dienophiles: Atom efficient one-pot synthesis of highly substituted cyclohexenes and cyclohexadienes. J Am Chem Soc 2001;123:8398–8399.
   PubMed Web of Science ®Google Scholar
• von Wangelin A, Neumann H, Gördes D, Klaus S, Strübing D, Beller M. Multicomponent coupling reactions for organic synthesis: chemoselective reactions with amide-aldehyde mixtures. Chem Eur J 2003;9:4286–4294.
   PubMed Web of Science ®Google Scholar
• Klaus S, Hübner S, Neumann H, Strübing D, von Wangelin A, Gördes D, Beller M. Second generation protocol for multicomponent coupling reactions of aldehydes, amides and dienophiles. Adv Synth Catal 2004;346:970–978.
   Web of Science ®Google Scholar
• Wendler C, Krüger-Sundhaus T, Beller M, Gördes D, Thurow K. Single-pot solution phase synthesis optimization using fully automated systems for combinatorial screening. J Assoc Lab Automation 2005;10:237–241.
   Google Scholar
• Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67–73.
   PubMed Web of Science ®Google Scholar
• Thurow K, Göde B, Dingerdissen U, Stoll N. Laboratory information management systems for life science applications. Organic Process Research and Development 2004;8:970–982.
   Web of Science ®Google Scholar
• Paolini M, Barillari J, Trespidi S, Valgimigli L, Pedulli GF, Cartelli-Forti G. Captan impairs CYP-catalyzed drug metabolism in the mouse. Chemico-Biol Interact 1999;123:149–170.
   PubMed Web of Science ®Google Scholar
• Peebles A, Dalvi RR. Toxicology studies of N-trichlormethylthio-4-cyclohexene-1,2-dicarboximide (Captan): Its metabolism by rat liver drug metabolizing enzyme system. Toxicology 1978;9:341–351.
   PubMed Web of Science ®Google Scholar
• Dalvi RR, Mutinga ML. Comparative studies of the effects on liver and liver microsomal drug-metabolizing enzyme system by the fungicides captan, captafol and folpet in rats. Pharmacol Toxicol 1990;66:231–233.
   PubMedGoogle Scholar
• Rahden-Staron I, Czeczot H, Szumilo M. Induction of rat liver cytochrome P450 isoenzymes CYP1A and CYP2B by different fungicides, nitrofurans and quercetin. Mut Res 2001;498:57–66.
   PubMed Web of Science ®Google Scholar
• Thomas H, Strolin-Benedetti M, Dostert P, Oesch F. The effect of indobufen on the activities of selected rat liver phase I and phase II drug metabolizing enzymes, peroxisomal beta-oxidation and hepatic glutathione status. J Pharm Pharmacol 1994;46:833–837.
   PubMed Web of Science ®Google Scholar
• Cruciani G, Carosati E, De Boeck B, Ethirajulu K, Mackie C, Howe T, Vianello R. MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist. J Med Chem 2006;48:6970–6979.
   Web of Science ®Google Scholar